Stockreport

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Omeros Corporation  (OMER) 
Last omeros corporation earnings: 3/2 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.omeros.com
PDF Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100 TA-TMA patients not treat [Read more]